The Board of Directors of L.O.M. Medical International Inc. and L.O.M. Laboratories Inc. is pleased to advise its shareholders that it has signed an Engagement Agreement with Deloitte Corporate Finance Inc. The purpose of the agreement is to retain Deloitte as Finance Advisor to L.O.M. and to have Deloitte provide advisory services with respect to a potential divestiture to L.O.M.’s retractable Syringe Technology.
Deloitte will work with the Company’s management team with the completion of transaction pre-planning through:
1. The review of all relevant Company materials including but not limited to, financial, medical, intellectual property (patents, licenses, trademarks, designs, etc.), market analysis, etc.;
2. Helping to develop a consensus regarding the financial potential for the opportunity including the development of a financial model to capture the value, including a review and assessment of key inputs to the model such as estimated pricing, volumes, sales ramp up, cost of sales, direct costs such as sales and marketing and direct operational costs.;
3. Working together on identifying comparable companies, comparable transactions (companies and assets), and other market based information to assist in the development of the financial model.; and
4. Working together to develop a range of possible estimates for a transaction price and structure for L.O.M.’s assets based on the above analysis.
It is anticipated by L.O.M. and Deloitte that the defined activities and services will be completed within 4 to 6 weeks. Management hopes to have further updates as they become available.